Polymyositis
53
7
8
34
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
11 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.5%
4 terminated out of 53 trials
89.5%
+2.9% vs benchmark
13%
7 trials in Phase 3/4
32%
11 of 34 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 34 completed trials
Clinical Trials (53)
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Adult and Juvenile Myositis
Environmental Risk Factors for the Anti-synthetase Syndrome
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
Add-on Intravenous Immunoglobulins in Early Myositis
Rheumatology Patient Registry and Biorepository
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
Study of M5049 in DM and PM Participants (NEPTUNIA)
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)